Gilder Gagnon Howe & Co. LLC Has $2.20 Million Position in ABIOMED, Inc. (NASDAQ:ABMD)
Gilder Gagnon Howe & Co. LLC raised its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 3.0% during the second quarter, according to its most recent filing with the SEC. The firm owned 15,347 shares of the medical equipment provider’s stock after buying an additional 446 shares during the period. Gilder Gagnon Howe & Co. LLC’s holdings in ABIOMED were worth $2,199,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Huntington National Bank purchased a new position in ABIOMED during the second quarter worth approximately $100,000. Creative Planning raised its position in ABIOMED by 16.4% in the first quarter. Creative Planning now owns 916 shares of the medical equipment provider’s stock worth $115,000 after buying an additional 129 shares during the period. Private Bank & Trust Co. purchased a new position in ABIOMED during the second quarter worth approximately $226,000. Virginia Retirement Systems ET AL purchased a new position in ABIOMED during the first quarter worth approximately $200,000. Finally, Palladium Partners LLC purchased a new position in ABIOMED during the first quarter worth approximately $211,000. 90.51% of the stock is currently owned by institutional investors and hedge funds.
Shares of ABIOMED, Inc. (NASDAQ:ABMD) opened at 155.85 on Thursday. The firm has a 50-day moving average of $145.21 and a 200-day moving average of $130.31. ABIOMED, Inc. has a one year low of $95.14 and a one year high of $157.41. The stock has a market cap of $6.84 billion, a PE ratio of 91.14 and a beta of 0.20.
ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.45 EPS for the quarter, topping the consensus estimate of $0.42 by $0.03. The firm had revenue of $132.47 million during the quarter, compared to analyst estimates of $130.83 million. ABIOMED had a net margin of 16.13% and a return on equity of 13.03%. ABIOMED’s revenue was up 28.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.29 EPS. On average, equities research analysts expect that ABIOMED, Inc. will post $2.24 earnings per share for the current fiscal year.
Several brokerages recently issued reports on ABMD. Zacks Investment Research lowered shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Monday. Jefferies Group LLC upped their target price on shares of ABIOMED from $165.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, August 4th. BidaskClub lowered shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Piper Jaffray Companies restated an “overweight” rating and set a $160.00 price target (up from $145.00) on shares of ABIOMED in a research report on Thursday, July 27th. Finally, William Blair restated an “outperform” rating on shares of ABIOMED in a research report on Thursday, June 8th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. ABIOMED currently has a consensus rating of “Buy” and a consensus price target of $158.29.
In other ABIOMED news, VP Michael G. Howley sold 18,279 shares of the business’s stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $133.56, for a total transaction of $2,441,343.24. Following the sale, the vice president now owns 62,105 shares of the company’s stock, valued at approximately $8,294,743.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO David M. Weber sold 16,500 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $147.63, for a total transaction of $2,435,895.00. Following the sale, the chief operating officer now directly owns 125,122 shares in the company, valued at approximately $18,471,760.86. The disclosure for this sale can be found here. Insiders own 7.00% of the company’s stock.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).
Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.